The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance
OPEN BMC medicine | 4 Nov 2016
F Gehre, J Otu, L Kendall, A Forson, A Kwara, S Kudzawu, AO Kehinde, O Adebiyi, K Salako, I Baldeh, A Jallow, M Jallow, A Dagnra, K Dissé, EA Kadanga, EO Idigbe, C Onubogu, N Onyejepu, A Gaye-Diallo, A Ba-Diallo, P Rabna, M Mane, M Sanogo, B Diarra, Z Dezemon, A Sanou, M Senghore, BA Kwambana-Adams, E Demba, T Faal-Jawara, S Kumar, LD Tientcheu, A Jallow, S Ceesay, I Adetifa, A Jaye, MJ Pallen, U D'Alessandro, B Kampmann, RA Adegbola, S Mboup, T Corrah, BC de Jong and M Antonio
Drug-resistant tuberculosis (TB) is a global public health problem. Adequate management requires baseline drug-resistance prevalence data. In West Africa, due to a poor laboratory infrastructure and inadequate capacity, such data are scarce. Therefore, the true extent of drug-resistant TB was hitherto undetermined. In 2008, a new research network, the West African Network of Excellence for Tuberculosis, AIDS and Malaria (WANETAM), was founded, comprising nine study sites from eight West African countries (Burkina Faso, The Gambia, Ghana, Guinea-Bissau, Mali, Nigeria, Senegal and Togo). The goal was to establish Good Clinical Laboratory Practice (GCLP) principles and build capacity in standardised smear microscopy and mycobacterial culture across partnering laboratories to generate the first comprehensive West African drug-resistance data.
* Data courtesy of Altmetric.com